This company has been acquired
Mirati Therapeutics Gestion
Gestion contrôle des critères 4/4
Mirati Therapeutics' CEO is Chuck Baum, appointed in Nov 2012, has a tenure of 11.17 years. total yearly compensation is $7.42M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $6.57M. The average tenure of the management team and the board of directors is 2.5 years and 5.1 years respectively.
Informations clés
Chuck Baum
Directeur général
US$7.4m
Rémunération totale
Pourcentage du salaire du PDG | 9.2% |
Durée du mandat du directeur général | 11.2yrs |
Propriété du PDG | 0.2% |
Durée moyenne d'occupation des postes de direction | 2.5yrs |
Durée moyenne du mandat des membres du conseil d'administration | 5.1yrs |
Mises à jour récentes de la gestion
Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Analyse de la rémunération des PDG
Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
---|---|---|---|
Sep 30 2023 | n/a | n/a | -US$726m |
Jun 30 2023 | n/a | n/a | -US$738m |
Mar 31 2023 | n/a | n/a | -US$737m |
Dec 31 2022 | US$7m | US$685k | -US$741m |
Sep 30 2022 | n/a | n/a | -US$738m |
Jun 30 2022 | n/a | n/a | -US$645m |
Mar 31 2022 | n/a | n/a | -US$634m |
Dec 31 2021 | US$18m | US$662k | -US$582m |
Sep 30 2021 | n/a | n/a | -US$483m |
Jun 30 2021 | n/a | n/a | -US$491m |
Mar 31 2021 | n/a | n/a | -US$407m |
Dec 31 2020 | US$12m | US$615k | -US$358m |
Sep 30 2020 | n/a | n/a | -US$329m |
Jun 30 2020 | n/a | n/a | -US$296m |
Mar 31 2020 | n/a | n/a | -US$259m |
Dec 31 2019 | US$8m | US$597k | -US$213m |
Sep 30 2019 | n/a | n/a | -US$169m |
Jun 30 2019 | n/a | n/a | -US$142m |
Mar 31 2019 | n/a | n/a | -US$125m |
Dec 31 2018 | US$5m | US$580k | -US$98m |
Sep 30 2018 | n/a | n/a | -US$88m |
Jun 30 2018 | n/a | n/a | -US$77m |
Mar 31 2018 | n/a | n/a | -US$67m |
Dec 31 2017 | US$2m | US$563k | -US$70m |
Rémunération vs marché: Chuck's total compensation ($USD7.42M) is about average for companies of similar size in the US market ($USD6.39M).
Rémunération et revenus: Chuck's compensation has been consistent with company performance over the past year.
PDG
Chuck Baum (65 yo)
11.2yrs
Titularisation
US$7,420,213
Compensation
Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...
Équipe de direction
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Founder | 11.2yrs | US$7.42m | 0.16% $ 6.6m | |
Executive VP & Chief Scientific Officer | 10yrs | US$5.01m | 0.082% $ 3.4m | |
Executive VP & Chief Medical Officer | 1.2yrs | US$5.30m | 0.014% $ 587.2k | |
Chief Financial Officer | less than a year | pas de données | 0.056% $ 2.3m | |
Chief Accounting Officer | less than a year | pas de données | pas de données | |
Chief Legal Officer & Corporate Secretary | less than a year | pas de données | pas de données | |
Chief Compliance Officer | 2yrs | pas de données | pas de données | |
Chief People Officer | 2yrs | pas de données | pas de données | |
Chief Commercial Officer | 4yrs | US$6.93m | 0.040% $ 1.6m | |
VP & Head of Medical Affairs | 3.8yrs | pas de données | pas de données | |
VP & Head of Corporate Affairs | 3.8yrs | pas de données | pas de données | |
Senior VP of Pharmacovigilance & Chief Safety Officer | 3yrs | pas de données | pas de données |
2.5yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: MRTX's management team is considered experienced (2.5 years average tenure).
Membres du conseil d'administration
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Founder | 11.2yrs | US$7.42m | 0.16% $ 6.6m | |
Independent Director | 7.3yrs | US$700.41k | 0.0086% $ 353.3k | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Chairman & Lead Independent Director | 4.9yrs | US$979.79k | 0.012% $ 511.8k | |
Independent Director | 4.6yrs | US$697.91k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Independent Director | 5.1yrs | US$677.91k | 0.061% $ 2.5m | |
Member of Scientific Advisory Board | 5yrs | pas de données | pas de données | |
Independent Director | 10.3yrs | US$702.91k | 0.0086% $ 353.3k | |
Member of Scientific Advisory Board | 5yrs | pas de données | pas de données | |
Independent Director | 5.1yrs | US$695.41k | 0.0086% $ 353.3k |
5.1yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Conseil d'administration expérimenté: MRTX's board of directors are considered experienced (5.1 years average tenure).